A class action lawsuit was filed against AstraZeneca Plc (AZN) by Levi & Korsinsky on December 23, 2024. The plaintiffs ...

In a report released today, Matthew Weston from UBS upgraded AstraZeneca (AZN – Research Report) to a Buy, with a price target of £142.00. The ...

AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

AstraZeneca could face a fine of up to $4.5 million in China over suspected unpaid taxes related to the import of two of its ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

Shares of AstraZeneca PLC (NASDAQ:AZN – Get Free Report) have been assigned an average recommendation of “Buy” from the ten brokerages that are currently covering the company, MarketBeat.com ...

These robust figures were mainly driven by a number of promising trials, with the company delivering nine positive high value Phase III studies during the full year 2024. AstraZeneca has seen ...

The AstraZeneca PLC ADR AZN rose 2.34% to $74.43 Wednesday, on what proved to be an all-around mixed trading session for the ...

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 18,745.88 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...